Market Place
Sourcing Support
Acadia nabs Lexicon alum as new commercial lead
11 Dec 2024 //
FIERCE PHARMA
Lexicon Completes Enrollment in Phase 2B Study of LX9211 in DPNP
26 Nov 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals to Attend December Investor Conferences
25 Nov 2024 //
GLOBENEWSWIRE
Lexicon to Reposition as Clinical Development-Focused Company
22 Nov 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals To Lay Off 60% After FDA Setback
22 Nov 2024 //
REUTERS
Lexicon Appoints Ivan H. Cheung to Board of Directors
20 Nov 2024 //
GLOBENEWSWIRE
Lexicon Presents Sotagliflozin Data at AHA 2024 in Chicago
14 Nov 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals to Attend Jefferies Healthcare Conference
06 Nov 2024 //
GLOBENEWSWIRE
Lexicon Pharma to Host Q3 2024 Results Call on Nov 12, 2024
05 Nov 2024 //
GLOBENEWSWIRE
Sotagliflozin Efficacy & Safety for Type 1 Diabetes at ASNKD
05 Nov 2024 //
GLOBENEWSWIRE
Lexicon Presents Preclinical Data on Semaglutide- Weight Loss
04 Nov 2024 //
GLOBENEWSWIRE
FDA advisers vote against Lexicon Pharma`s add-on drug for T1D
04 Nov 2024 //
REUTERS
Lexicon Reports FDA Advisory Committee Outcome for Zynquista™
31 Oct 2024 //
GLOBENEWSWIRE
New Phase 3 Data on Sotagliflozin to be Presented at ASN 2024
23 Oct 2024 //
GLOBENEWSWIRE
Lexicon Completes Screening In Phase 2B Study Of LX9211
22 Oct 2024 //
GLOBENEWSWIRE
Viatris Announces Licenses Sotagliflozin Outside U.S. And Europe
16 Oct 2024 //
PR NEWSWIRE
Lexicon Announces Licensing Agreement With Viatris For Sotagliflozin
16 Oct 2024 //
GLOBENEWSWIRE
Viatris lays out $25M to tackle marketing of Lexicon`s Inpefa
15 Oct 2024 //
FIERCE PHARMA
Lexicon To Present Phase 3 Trial Design For Sotagliflozin In HCM
27 Sep 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Announces Departure Of President
16 Sep 2024 //
GLOBENEWSWIRE
nVNS Effective In Accelerating Air Force Pilot Training
10 Sep 2024 //
GLOBENEWSWIRE
Analysis Shows INPEFA Benefits Heart Failure Patients Irrespective of Diabetes
03 Sep 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals to Attend September Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
21 Aug 2024 //
GLOBENEWSWIRE
Lexicon Pharma Announces Strategic Repositioning For Growth
13 Aug 2024 //
GLOBENEWSWIRE
Lexicon Presents Sotagliflozin Data At Diabetes Care Specialists Conference
07 Aug 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Reports Q2 2024 Results And Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals To Host Q2 Results Call On August 1
25 Jul 2024 //
GLOBENEWSWIRE
Lexicon Gets Dec 20 PDUFA Date For Sotagliflozin T1D NDA Resubmission
16 Jul 2024 //
GLOBENEWSWIRE
New Data Shows Potential Cost-Savings Of INPEFA For Heart Failure
15 Jul 2024 //
GLOBENEWSWIRE
Lexicon Appoints Mike Exton, Ph.D. As New CEO And Director
08 Jul 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
21 Jun 2024 //
GLOBENEWSWIRE
Lexicon`s Phase 2 Study Data Published In Diabetes Care
19 Jun 2024 //
GLOBENEWSWIRE
INPEFA® (Sotagliflozin) Cost-Effectiveness Analysis Published In JACC
18 Jun 2024 //
GLOBENEWSWIRE
Lexicon Presents DPNP Burden Findings At ADA 84th Sessions
14 Jun 2024 //
GLOBENEWSWIRE
Lexicon At Jefferies Healthcare Conference 2024
29 May 2024 //
GLOBENEWSWIRE
Lexicon Picks Medidata For Non-Opioid Neuropathic Pain Drug
29 May 2024 //
BUSINESSWIRE
INPEFA Reduced Heart Failure Risk In Preserved EF, Pooled Analysis Shows
14 May 2024 //
GLOBENEWSWIRE
Lexicon Pharma At BofA Healthcare Conference 2024
09 May 2024 //
GLOBENEWSWIRE
Lexicon Pharma Q1 2024 Results, Business Update
02 May 2024 //
GLOBENEWSWIRE
Lexicon Pharma Q1 2024 Call on May 2
29 Apr 2024 //
GLOBENEWSWIRE
Lonnel Coats Retires as Lexicon CEO & Board Member
29 Apr 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals to Host 2024 Investor Day
18 Apr 2024 //
GLOBENEWSWIRE
Lexicon to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03 Apr 2024 //
GLOBENEWSWIRE
Clinical Data on Impact of Sotagliflozin on StrokeHeart Attack Risk Four Lexicon
25 Mar 2024 //
GLOBENEWSWIRE
Lexicon preps FDA resubmission for diabetes hopeful Zynquista
12 Mar 2024 //
FIERCE PHARMA
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes
11 Mar 2024 //
GLOBENEWSWIRE
Lexicon Announces $250 Million Private Placement of Equity Securities
11 Mar 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results
11 Mar 2024 //
GLOBENEWSWIRE
Lexicon Pharmaceuticals Provides Business and Pipeline Update
08 Jan 2024 //
GLOBENEWSWIRE
Lexicon To Participate In The 42nd Annual JPMorgan Healthcare Conference
21 Dec 2023 //
GLOBENEWSWIRE
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211
30 Nov 2023 //
GLOBENEWSWIRE
Lexicon to Participate in the 35th Annual Piper Sandler Healthcare Conference
22 Nov 2023 //
GLOBENEWSWIRE
INPEFA Use Associated With Early Clinical Benefit in Heart Failure
12 Nov 2023 //
GLOBENEWSWIRE
Lexicon to Participate in the Jefferies London Healthcare Conference
10 Nov 2023 //
GLOBENEWSWIRE
Lexicon Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
GLOBENEWSWIRE
Lexicon to Host Third Quarter 2023 Financial Results Conference
03 Nov 2023 //
GLOBENEWSWIRE
Data on Benefit for INPEFA Will Be Among Five Lexicon-Sponsored Presentations
02 Nov 2023 //
GLOBENEWSWIRE
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts
01 Nov 2023 //
GLOBENEWSWIRE
